Sanofi moves up on launching multiple sclerosis treatment drug in India

07 Aug 2018 Evaluate

Sanofi India is currently trading at Rs. 6168.00, up by 56.25 points or 0.92% from its previous closing of Rs. 6111.75 on the BSE.

The scrip opened at Rs. 6129.95 and has touched a high and low of Rs. 6243.45 and Rs. 6129.95 respectively. So far 657 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 6,243.45 on 07-Aug-2018 and a 52 week low of Rs. 3901.00 on 06-Sep-2017.

Last one week high and low of the scrip stood at Rs. 6,243.45 and Rs. 5,950.00 respectively. The current market cap of the company is Rs. 14197.23 crore.

The promoters holding in the company stood at 60.40%, while Institutions and Non-Institutions held 28.22% and 11.38% respectively.

Sanofi’s specialty care global business unit -- Sanofi Genzyme has launched its multiple sclerosis treatment drug ‘Aubagio’ in India. The drug offers patients diagnosed with multiple sclerosis the efficacy and convenience of once-a-day oral treatment.

Aubagio is a differentiated disease modifying therapy that blocks the enzyme involved in multiplication of overactive immune cells.

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.

Sanofi India Share Price

4334.40 -37.30 (-0.85%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×